



U.S. Department of Justice

*United States Attorney  
District of Massachusetts*

Main Reception: (617) 748-3100

*United States Courthouse, Suite 9200  
1 Courthouse Way  
Boston, Massachusetts 02210*

December 15, 2011

By TELEFAX and Email  
202-778-5281

Geoffrey Hobart, Esq.  
Covington & Burling  
1210 Pennsylvania Avenue, NW  
Washington, DC 20004-3401

Re: GlaxoSmithKline: Tolling Agreement on Statute of Limitations

Dear Mr. Hobart:

This letter confirms and sets forth an agreement between the Office of the United States Attorney for the District of Massachusetts and your client, SmithKlineBeecham Corporation d/b/a GlaxoSmithKline, and all successors and assigns (hereinafter "GSK"). The terms of the agreement are as follows:

1. As you are aware, this Office is presently conducting a joint criminal and civil investigation of your client, GSK, and its officers, employees and agents. That conduct includes, without limitation, allegations that GSK and certain of its officers, employees and agents, may have violated various federal criminal statutes, including but not limited to 18 U.S.C. §371 (conspiracy to defraud the United States), 42 U.S.C. §1320(a)-7(b) (criminal penalties for acts involving the Medicare and State health care programs), 18 U.S.C. § 1001 (making false or fraudulent statements), 21 U.S.C. § 301, et seq. (Food Drug & Cosmetic Act), health care fraud offenses (e.g. 18 U.S.C. §§ 669, 1347, and 1035), certain civil statutes including but not limited to 31 U.S.C. § 3729 (civil False Claims Act); and certain administrative statutes such as 42 U.S.C. § 1320a-7 (exclusion) and 42 U.S.C. § 1320a-7a (civil monetary penalties) in connection with (a) GSK's distribution in interstate commerce of the Covered Drugs (as defined in the HIPAA subpoena dated February 6, 2004) that were adulterated, misbranded and/or had not yet been approved for commercial distribution by the United States Food and Drug Administration ("FDA"); and (b) GSK's activities in connection with the distribution, sale, marketing, approval, and promotion of the Covered Drugs, including its communications with the FDA about these subjects.

2. In the course of our discussions, this Office has expressed its intention to afford you and your client the fullest opportunity to provide information to this Office which you deem relevant to matters relating to that investigation. In response, you have advised us that you intend to provide certain information to this Office, and that you wish such information be considered prior to a prosecution decision concerning potential criminal charges resulting from that investigation. You have advised this Office that you and members of your firm will require a further time period to prepare any materials and gather information for presentation to this Office, and to consider and evaluate further information as may be provided by this Office. As a result, this Office and your client have agreed, as more fully set forth below, to toll the applicable statutes of limitations for the offenses described in paragraph one for the time period October 19, 2005 through September 15, 2012 for that conduct described in paragraph one.

3. This Office and your client, GSK, hereby agree that your client will not at any time interpose a statute of limitations defense or any constitutional claim based upon pre-indictment delay to any indictment or count thereof, or to any civil complaint or count thereof, or to any administrative action, which charges or alleges that your client committed any federal offense or violation related to the conduct described in paragraph one, that includes the time period October 19, 2005 to September 15, 2012 in the calculation of the limitations period. Nothing herein shall affect, or be construed as any waiver of, any applicable statute of limitations defenses that GSK may have with respect to the time period prior to and including October 19, 2005, and your client expressly reserves its right to raise any such defense, any provisions of this agreement notwithstanding, except to the extent that your client has waived certain statute of limitation defenses in any waiver agreement(s) with other United States Attorney's Offices or the Department of Justice, which agreement(s) remain in effect.

4. Your client, GSK, enters into this agreement knowingly and voluntarily. GSK acknowledges that the statute of limitations and United States Constitution regarding prejudicial pre-indictment delay confers benefits on it, and it is not required to waive those benefits, and that GSK is doing so after consulting with you because GSK believes it is in its best interest to do so. GSK also acknowledges its understanding that it may be charged with the foregoing criminal offenses and civil and administrative violations and/or any other offenses or violations at any time prior to and including September 15, 2012. GSK further acknowledges its understanding that it may be charged with any offenses or violations not specifically described above, at any time during the relevant statute of limitations period.


5. This agreement relates only to the allegations described in paragraph one above and any charges or claims based on those allegations. This writing contains the entire agreement between this Office and your client concerning the statute of limitations with respect to these matters and can be modified or supplemented only by means of a writing signed by this Office and your client.

If your client is willing to enter into this agreement on the terms set forth above, GSK should indicate the same by signing on the spaces provided below.


Very truly yours,

CARMEN M. ORTIZ  
United States Attorney

By:




~~/s/ Sara M. Bloom~~  
Susan G. Winkler  
Sara M. Bloom  
Assistant U.S. Attorneys



Dated: 12/20/11

Geoffrey Hobart  
Covington & Burling  
Attorney for GSK



Dated: 12/15/11

Elpidio Villareal, Senior Vice President,  
Global Litigation  
GlaxoSmithKline LLC